EA1211：预测her2阳性乳腺癌对新辅助治疗反应的中期FDG-PET/CT（直接试验）。

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-10-05 DOI:10.1080/14796694.2025.2567840

Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, Roisin M Connolly, Brian L Burnette, Erica M Stringer-Reasor, Justin Romanoff, Alexander Taurone, Ciara C O'Sullivan, Huong T Le-Petross, Vered Stearns, Amy M Fowler, Shou-Ching Tang, Karla A Sepulveda, Angela M DeMichele, David A Mankoff, Antonio C Wolff

引用次数: 0

摘要

临床试验注册：NCT05710328。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).

Clinical trial registration: NCT05710328.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.